Drug intelligence / Profile preview

SB101

Development stage: Preclinical
Lead developer: Shift Bioscience
Modality: Small Molecules

Overview

SB101 is a preclinical-stage small molecule therapeutic being developed by Shift Bioscience for the treatment of systemic sclerosis. Developed using the company's proprietary computational platform, which identifies targets related to cellular aging and rejuvenation, SB101 is intended to address the multi-organ fibrotic manifestations of the disease. While the specific biological target and mechanism of action have not been publicly disclosed, the candidate represents Shift Bioscience's application of aging-related biological insights to autoimmune and fibrotic conditions.

Targets

IL11 (Interleukin-11)

Beyond the preview

Go deeper on SB101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SB101.

Explore the full profile